Table 2.

Schedule for enrollment, interventions, and assessments.

Time point	Study period
	Enrollment	Allocation	Post-allocation
	-t1	t1	t2	t3
		(Week 0)	(Week 12)	(Week 24)
Enrollment
Eligibility screen	×
Informed consent	×
Allocation		×
Interventions
Tablet 1 and placebo 1
Tablet 2 and placebo 1
Tablet 3 and placebo 1
Tablet 4 and placebo 1
Tablet 4 and capsule 1
Placebo 1 and placebo 2
Assessments
Demographics	×
Lifestyle behaviors	×		×	×
Medical history and medications	×		×	×
Dietary assessment	×		×	×
Anthropometry	×		×	×
MPOD	×		×	×
UCVA and BCVA	×		×	×
CS and GS	×		×	×
CFF	×		×	×
Reaction time	×		×	×
Visuognosis persistence	×		×	×
Symptoms and signs of DED	×			×
Retinal thickness	×			×
Optical quality	×			×
DNA extraction and genotyping		×
Fasting blood (e.g., serum lutein and zeaxanthin, RBC membrane omega-3 fatty acids)		×	×	×
Stool samples for microbiome analysis		×		×
Provided supply of supplements		×	×
Adverse events		×	×	×
Collect unused test product			×	×

t₁, baseline; t₂, at 12 weeks; t₃, at 24 weeks; MPOD, macular pigment optical density; UCVA, uncorrected visual acuity; BCVA, best-corrected visual acuity; CS, contrast sensitivity; GS, glare sensitivity; CFF, critical flicker fusion; DED, dry eye disease; RBC, red blood cell.